SpringerImages - Concordance rate between CellSearch assay and AdnaTest

The meeting will provide an overview of novel assay platforms for genomic and .

Concordance with CellSearch Assay and Association with. Bone Metastases and

Jun 1, 2008 . [1] Treatment of metastatic breast cancer (MBC) imposes a . (FDA) cleared the

Jun 16, 2009 . CellSearch assay (Veridex, LLC, Raritan,. NJ) does not detect cultured human

breast cancer centers were enrolled in this prospective study. HER2 status of

Dec 15, 2009 . Cancer Research: December 15, 2009; Volume 69, Issue 24, . 48% (28 of 41)

May 19, 2011 . Both the CellSearch assay and AdnaTest BreastCancer™ (Adnagen AG,

Sixty-two patients (28%) were CTC positive by both methods, whereas either the

Now that Veridex's assay for metastatic breast cancer has received FDA

Circulating tumour cells as tumour markers from Advances in Breast Cancer. .

At the time this LCD was written and published the Cell Search (Veridex ) . Cell

However, in prostate cancer patients the new assay has shown greater sensitivity

Aug 9, 2011 . A direct comparison of CellSearch and ISET for circulating . of the EpCAM

Jul 7, 2008. for use in patients with metastatic breast cancer as an aid to monitoring . and

Feb 26, 2007 . using newly developed CellSearch Assay. . urothelial cancers by CellSearch

Dec 31, 2008 . CellSearch is an antibody-based test, approved by the U.S. Food . The assay

One of the CTC detection methods (Veridex Inc, Cell Search Assay) has been .

Barrett's BioStrat Assay · Prostate BioStrat Assay . Another, newer method for

The Breast Cancer Research Foundation . LLC CellSearch assay for detecting

Sep 22, 2010 . HER2 status of CTCs was assessed using both the FDA-approved CellSearch®

Jul 16, 2007 . The GeneSearch™ Breast Lymph Node (BLN) Assay can detect the spread of . “

FDA-Cleared Assays. ▪ Metastatic breast cancer. ▪ #89089 Circulating Tumor

Feb 15, 2011 . breast cancer, in early detection of relapse and in monitoring the . .. of

One of the first published papers in the field, by renowned breast cancer . . bias

Jun 1, 2011 . Breast Cancer Res Treat. . Blood samples were subjected to both the OBP-401

treatment decisions in patients with breast cancer. Similarly, the use of the

The CellSearch assay is FDA approved in the United States as a prognostic test

“Say a patient has circulating breast cancer cells,” says Dr. Halling, . MD, who

Related. Communiqué: The CellSearch Assay for Circulating Tumor Cells: An

May 15, 2011 . Patients with metastatic breast, colorectal, or prostate cancer, prior to a new .

HER2 status of CTCs was assessed using both the FDA-approved CellSearch

Jun 5, 2011 . Management of prostate cancer is recognized as one of the most important .

Apr 20, 2011 . Only approximately 10% of patients with stage I and II breast cancer have .

Jun 9, 2009 . (1) reported that the CellSearch assay (Veridex, LLC, Raritan, NJ) does not

Jun 1, 2011 . Breast Cancer Research and Treatment (1 June 2011), pp. 1-9. . The

But, only a few attempts have been made at the detection of urothelial cancer

The CellSearch™ system (Veridex) is an example of immunofluorescent .

Aug 11, 2011 . This phenomenon is becoming increasingly problematic as the size of breast

The CellSearch Circulating Tumor Cell assay is the first and only assay to date .

Metastatic Breast Cancer . Key Benefit of Using the CellSearch™ CTC Test .

Mar 22, 2011 . (28 of 57) using the CellSearch assay and AdnaTest BreastCancer, respectively.

Feb 29, 2008 . The CellSearch™ System identifies and counts circulating tumor . In August

Jul 11, 2011 . Breast Cancer Research 2011, 13:R71 doi:10.1186/bcr2916 . . Detection of CTC

Circulating Tumor Cells (CTC) for Breast Cancer by CellSearch, Blood (89089) .

Mar 21, 2011 . cleared the CellSearch assay for clinical use, the American Society . static

Dec 2, 2004 . A prospective study of the CellSearch assay in patients with bone-only metastatic

CellSearch Circulating Tumor Cells, Breast Cancer: Predict progression-free

Patients with metastatic breast, colorectal, or prostate cancer, prior to a new

Twenty-eight patients with non-small cell lung cancer and hematogenously

Sitemap